Trial · NCT04051463
Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
NCT04051463, Phase 2, Phase 3, Completed, Price Vision Group; results first posted 2021-09-24
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rhopressa for Corneal Edema Associated With Fuchs Dystrophy. Trials, record NCT04051463. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04051463
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rhopressa for Corneal Edema Associated With Fuchs Dystrophy
- NCT number
- NCT04051463
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 29 participants, actual
- Lead sponsor
- Price Vision Group
- Conditions
- Fuchs Endothelial Dystrophy
- Interventions
- Netarsudil Ophthalmic Solution, Placebo
- First posted
- 2019-08-09
- Last updated
- 2021-10-19
- Results first posted
- 2021-09-24
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Central Corneal Thickness | 1 month | Central corneal thickness at 1 month after randomization minus central corneal thickness at baseline |
| Secondary | Change in Corrected Distance Visual Acuity (CDVA) | 3 months | Change in CDVA (lines read on the eye chart at 3 months minus lines read at baseline) |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Central Corneal Thickness | 1 month | microns | MEAN | |
| SECONDARY | Change in Corrected Distance Visual Acuity (CDVA) | 3 months | lines on the eye chart | MEAN |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Central Corneal Thickness | Netarsudil | -23 | 95% Confidence Interval -32 to -13 | microns | |
| Change in Central Corneal Thickness | Placebo | -2 | 95% Confidence Interval -9 to 5 | microns | |
| Change in Corrected Distance Visual Acuity (CDVA) | Netarsudil | 1.9 | 95% Confidence Interval 0.8 to 3 | lines on the eye chart | |
| Change in Corrected Distance Visual Acuity (CDVA) | Placebo | 0.3 | 95% Confidence Interval -0.7 to 1.3 | lines on the eye chart |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Netarsudil | 15 | |
| Overall Study | STARTED | Placebo | 14 | |
| Overall Study | COMPLETED | Netarsudil | 13 | |
| Overall Study | COMPLETED | Placebo | 13 | |
| Overall Study | NOT COMPLETED | Netarsudil | 2 | |
| Overall Study | NOT COMPLETED | Placebo | 1 |
Source ClinicalTrials.gov
Adverse events8
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | conjunctival hyperemia | Eye disorders | Netarsudil | 6 | 15 | 6 |
| other | conjunctival hyperemia | Eye disorders | Placebo | 3 | 14 | 3 |
| other | ocular irritation | Eye disorders | Netarsudil | 2 | 15 | 2 |
| other | ocular irritation | Eye disorders | Placebo | 1 | 14 | 1 |
| other | glare | Eye disorders | Netarsudil | 1 | 15 | 1 |
| other | glare | Eye disorders | Placebo | 0 | 14 | 0 |
| other | lacrimation | Eye disorders | Netarsudil | 0 | 15 | 0 |
| other | lacrimation | Eye disorders | Placebo | 1 | 14 | 1 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Netarsudil | 0 | 15 |
| Total, all-cause mortality | Placebo | 0 | 14 |
| Total, other adverse events | Netarsudil | 6 | 15 |
| Total, other adverse events | Placebo | 3 | 14 |
| Total, serious adverse events | Netarsudil | 0 | 15 |
| Total, serious adverse events | Placebo | 0 | 14 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33737034 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Netarsudil vs Placebo: deaths from any cause | Trial comparisons |
| Netarsudil vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04051463
GET https://conductscience.org/api/trials/v1/NCT04051463/registered